BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 05, 2007
 |  BioCentury  |  Finance

EPS watch

EPS watch

EPS watch
United Therapeutics tacked on $619.3M, about 40%, in valuation last week after a double dose of good news. The company posted earnings that beat the Street concensus and reported that its Viveta met the primary endpoint in the Phase III TRIUMPH-1 trial to treat pulmonary arterial hypertension (PAH) (see "Phase III Reckoning," A16). Sepracor (SEPR) also enjoyed a double-digit percent jump last week on the heels of strong earnings and cost-cutting measures. Mcap in $M
Company 3Q07 EPS est 3Q07 EPS actual Outcome Growth from 3Q06 11/2 cls Wk chg % chg Mcap chg 11/2 Mcap
Alkermes (ALKS) (A) $0.04 $0.07 Beat by $0.03 75% $14.19 -$3.03 -18% -$307.8 $1,441.6
Excluding share-based compensation and a net change in the fair value of warrants, EPS rose 10% to $0.11 from $0.10 in 3Q06. Revenues were off 4% to $58.6M from $61.2M in fiscal 2Q07, driven mainly by lower Vivitrol-related revenues. The drug for alcohol dependence is partnered with Cephalon (CEPH). Royalty and manufacturing revenues for schizophrenia drug Risperdal Consta, sold by Johnson & Johnson (JNJ), came in at $30.2M,...

Read the full 1016 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >